Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
258 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape. Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 16, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology). - The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Gastrointestinal Stromal Tumor (GIST) - Overview 8 Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 16 Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 20 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 27 AB Science SA 27 Advanced Accelerator Applications SA 27 Advenchen Laboratories LLC 28 Ariad Pharmaceuticals Inc 28 Arog Pharmaceuticals Inc 29 ArQule Inc 29 Array BioPharma Inc 30 Astex Pharmaceuticals Inc 30 Blueprint Medicines Corp 31 Boston Biomedical Inc 31 Calithera Biosciences Inc 32 Celldex Therapeutics Inc 32 Chipscreen Biosciences Ltd 33 CytRx Corp 33 Deciphera Pharmaceuticals LLC 34 Exelixis Inc 34 F. Hoffmann-La Roche Ltd 35 Hanmi Pharmaceuticals Co Ltd 35 Horizon Pharma Plc 36 Immunicum AB 36 Jiangsu Hengrui Medicine Co Ltd 37 Natco Pharma Ltd 37 Nerviano Medical Sciences Srl 38 Novartis AG 38 Omeros Corp 39 Pharma Mar SA 39 Plexxikon Inc 40 Rhizen Pharmaceuticals SA 40 Taiho Pharmaceutical Co Ltd 41 Gastrointestinal Stromal Tumor (GIST) - Drug Profiles 42 aldoxorubicin hydrochloride - Drug Profile 42 amcasertib - Drug Profile 59 apatinib - Drug Profile 62 ARQ-092 - Drug Profile 67 binimetinib - Drug Profile 70 BLU-285 - Drug Profile 79 buparlisib hydrochloride - Drug Profile 83 cabozantinib s-malate - Drug Profile 89 CB-839 - Drug Profile 108 CDX-0158 - Drug Profile 116 CHMFLKIT-110 - Drug Profile 119 crenolanib besylate - Drug Profile 120 CS-2164 - Drug Profile 124 dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 125 DCC-2618 - Drug Profile 133 everolimus - Drug Profile 135 HM-95573 - Drug Profile 147 interferon gamma-1b - Drug Profile 149 Intuvax - Drug Profile 154 masitinib - Drug Profile 160 nilotinib - Drug Profile 176 NMSP-088 - Drug Profile 182 NRCAN-019 - Drug Profile 183 onalespib - Drug Profile 185 Peptide to Antagonize GRPR for Oncology - Drug Profile 189 pexidartinib - Drug Profile 190 PLX-9486 - Drug Profile 195 PM-184 - Drug Profile 196 ponatinib hydrochloride - Drug Profile 198 SF-1126 - Drug Profile 214 SHR-1020 - Drug Profile 216 Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 218 Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 219 TAS-116 - Drug Profile 220 TGR-1202 - Drug Profile 221 vemurafenib - Drug Profile 230 WBZ-4 - Drug Profile 237 Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 238 Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 239 Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 240 Featured News & Press Releases 240 Appendix 255 Methodology 255 Coverage 255 Secondary Research 255 Primary Research 255 Expert Panel Validation 255 Contact Us 255 Disclaimer 256
List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by CytRx Corp, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
